Valerie M. Mulligan
No más puestos en curso
Perfil
Valerie M.
Mulligan has been Senior Vice President-Quality and Regulatory Affairs for Neose Technologies, Inc. since March 2007.
Previously, she joined at Neose Technologies in 1996 as Manager-Quality Assurance and Vice President-Quality and Regulatory Affairs from October 2005 to March 2007.
Ms. Mulligan was Manager-Corporate Quality Assurance Engineering of Ethicon, Inc. from 1992 to 1996.
She received a BS degree in Chemistry and a post-graduate Diploma in Education from the University College in Dublin.
Antiguos cargos conocidos de Valerie M. Mulligan.
| Empresas | Cargo | Fin |
|---|---|---|
Neose Technologies, Inc.
 Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | Consejero General | 08/07/2010 |
Ethicon, Inc.
 Ethicon, Inc. Medical SpecialtiesHealth Technology Ethicon, Inc. develops and markets medical products and devices for surgery. It offers different types of services such as wound management, women's health, and cardiovascular surgery. The company was founded by George F. Merson in 1915 and is headquartered in Somerville, NJ. | Corporate Officer/Principal | 01/01/1996 |
Formación de Valerie M. Mulligan.
| University College Dublin | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | Health Technology |
Ethicon, Inc.
Ethicon, Inc. Medical SpecialtiesHealth Technology Ethicon, Inc. develops and markets medical products and devices for surgery. It offers different types of services such as wound management, women's health, and cardiovascular surgery. The company was founded by George F. Merson in 1915 and is headquartered in Somerville, NJ. | Health Technology |
- Bolsa de valores
- Insiders
- Valerie M. Mulligan
